我们可以缓解治疗HER2阳性转移性乳腺癌吗?
Laura A Huppert1, Hope S Rugo2
1University of California, San Francisco, California.
概括
一个Ib/II期试验发现,结合图卡丁尼布,莱特和palbociclib治疗HR+/HER2+转移性乳腺癌显示出良好的结果. 这种全口服,无化疗的治疗方案提供了一个有前途的治疗选择.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 转移性乳腺癌 (MBC) 具有激素受体阳性 (HR+) 和人体表皮生长因子受体2-阳性 (HER2+) 亚型,存在独特的治疗挑战.
- 目前的治疗策略通常涉及化疗,这可能会产生显著的副作用.
研究的目的:
- 评估一种新的全口服,无化疗方案的安全性和有效性,该方案结合了图卡提尼布,莱特和palbociclib.
- 探索这种组合作为HR+/HER2+MBC的维持或初级治疗的潜力.
主要方法:
- 第Ib/II期临床试验设计.
- 组合治疗涉及图卡丁尼布 (一种氨酸激酶抑制剂),莱特 (一种芳香酶抑制剂) 和palbociclib (一种CDK4/6抑制剂).
- 对HR+/HER2+转移性乳腺癌患者的安全性概况和疗效终点的评估.
主要成果:
- 组合疗法显示出可管理的安全性.
- 在患者队列中观察到令人鼓舞的疗效数据.
- 治疗的全口服,无化疗性质被强调为关键优势.
结论:
- 图卡提尼布,莱特和palbociclib的组合是一种可行的,可能有效的治疗HR+/HER2+转移性乳腺癌.
- 这种疗法对精选患者来说是一个有吸引力的无化疗策略.
- 需要进一步的研究来确定其作为初级或维持疗法的作用.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
231
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
231


